Comorbid autoimmune disorders are increasingly recognized in multiple sclerosis (MS), yet their integrated management remains a clinical challenge.
Report:
A 28-year-old female with MS was diagnosed with ulcerative colitis (UC). Upon initiation of cladribine therapy for MS, she achieved a state of UC remission: 4 years later, she experienced a relapse of both conditions and was treated with ozanimod, approved for MS (2020) and UC (2021).
Discussion:
This case highlights cladribine’s potential in managing both MS and UC, though its efficacy faded over time. Further research into shared immunopathogenesis and therapeutic strategies in co-existing autoimmune diseases is warranted.
SandbornWJFeaganBGD’HaensG, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med2021; 385: 1280–1291.
4.
FronzaMLoreficeLFrauJ, et al. An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis. Drug Des Devel Ther2021; 15: 1993–2004.
5.
GiovannoniG.Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics2017; 14(4): 874–887.
6.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
7.
SchubertCSteinbergLPeperJ, et al. Postpartum relapse risk in multiple sclerosis: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry2023; 94(9): 718–725.
8.
YuAFriedmanSAnanthakrishnanAN.Incidence and predictors of flares in the postpartum year among women with inflammatory bowel disease. Inflamm Bowel Dis2020; 26: 1926–1932.
9.
YuAFriedmanSAnanthakrishnanAN.Characteristics and long-term outcomes of pregnancy-onset inflammatory bowel disease: A case-control study. Inflamm Bowel Dis2021; 27: 476–481.
10.
BresciGParisiGBertoniM, et al. Long-term maintenance treatment in ulcerative colitis: A 10-year follow-up. Dig Liver Dis2002; 34(6): 419–423.
